Sutro Biopharma is a clinical-stage company developing next-generation antibody-drug conjugates (ADCs) for cancer. Its proprietary cell-free protein synthesis platform enables precise, site-specific design of antibodies, linkers and payloads—including multi-payload constructs—with the aim of improving stability, exposure and therapeutic index. Programs target solid tumors and other oncology indications where conventional ADCs leave room for optimization.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 63.7 | — | -11.5 | — |
| Q3 2025 | 9.7 | — | -56.9 | — |
| Q4 2025 | 11.7 | — | -46.8 | — |
| Q1 2026 | 14.5 | — | -38.5 | — |
| Q2 2026 | 9.8 | -84.6% | -38.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Magnitude International Ltd (MAGH), CAMP4 THERAPEUTICS CORPORATION (CAMP), Utah Medical Products, Inc. (UTMD), Apogee Acquisition Corp (AACP), SPACSphere Acquisition Corp. (SSAC), Ribbon Communications Inc. (RBBN)